145 related articles for article (PubMed ID: 10755474)
1. Genetic variations of S-mephenytoin 4'-hydroxylase (CYP2C19) in the Chinese population.
Xie HG
Life Sci; 2000 Feb; 66(14):PL175-81. PubMed ID: 10755474
[TBL] [Abstract][Full Text] [Related]
2. CYP2C19 genotype and S-mephenytoin 4'-hydroxylation phenotype in a Chinese Dai population.
He N; Yan FX; Huang SL; Wang W; Xiao ZS; Liu ZQ; Zhou HH
Eur J Clin Pharmacol; 2002 Apr; 58(1):15-8. PubMed ID: 11956668
[TBL] [Abstract][Full Text] [Related]
3. Genetic polymorphism of (S)-mephenytoin 4'-hydroxylation in populations of African descent.
Xie HG; Kim RB; Stein CM; Wilkinson GR; Wood AJ
Br J Clin Pharmacol; 1999 Sep; 48(3):402-8. PubMed ID: 10510153
[TBL] [Abstract][Full Text] [Related]
4. S-mephenytoin hydroxylation phenotype and CYP2C19 genotype among Ethiopians.
Persson I; Aklillu E; Rodrigues F; Bertilsson L; Ingelman-Sundberg M
Pharmacogenetics; 1996 Dec; 6(6):521-6. PubMed ID: 9014201
[TBL] [Abstract][Full Text] [Related]
5. A new genetic defect in human CYP2C19: mutation of the initiation codon is responsible for poor metabolism of S-mephenytoin.
Ferguson RJ; De Morais SM; Benhamou S; Bouchardy C; Blaisdell J; Ibeanu G; Wilkinson GR; Sarich TC; Wright JM; Dayer P; Goldstein JA
J Pharmacol Exp Ther; 1998 Jan; 284(1):356-61. PubMed ID: 9435198
[TBL] [Abstract][Full Text] [Related]
6. Allelic, genotypic and phenotypic distributions of S-mephenytoin 4'-hydroxylase (CYP2C19) in healthy Caucasian populations of European descent throughout the world.
Xie HG; Stein CM; Kim RB; Wilkinson GR; Flockhart DA; Wood AJ
Pharmacogenetics; 1999 Oct; 9(5):539-49. PubMed ID: 10591534
[TBL] [Abstract][Full Text] [Related]
7. Frequencies of defective CYP2C19 alleles in a Hong Kong Chinese population: detection of the rare allele CYP2C19*4.
Garcia-Barceló M; Chow LY; Kum Chiu HF; Wing YK; Shing Lee DT; Lam KL; Waye MM
Clin Chem; 1999 Dec; 45(12):2273-4. PubMed ID: 10585366
[No Abstract] [Full Text] [Related]
8. Evidence that poor metabolizers of (S)-mephenytoin could be identified by haplotypes of CYP2C19 in Japanese.
Takakubo F; Kuwano A; Kondo I
Pharmacogenetics; 1996 Jun; 6(3):265-7. PubMed ID: 8807668
[TBL] [Abstract][Full Text] [Related]
9. Evidence for the effect of gender on activity of (S)-mephenytoin 4'-hydroxylase (CYP2C19) in a Chinese population.
Xie HG; Huang SL; Xu ZH; Xiao ZS; He N; Zhou HH
Pharmacogenetics; 1997 Apr; 7(2):115-9. PubMed ID: 9170148
[TBL] [Abstract][Full Text] [Related]
10. Phenotypic-genotypic analysis of CYP2C19 in the Jewish Israeli population.
Sviri S; Shpizen S; Leitersdorf E; Levy M; Caraco Y
Clin Pharmacol Ther; 1999 Mar; 65(3):275-82. PubMed ID: 10096259
[TBL] [Abstract][Full Text] [Related]
11. An additional defective allele, CYP2C19*5, contributes to the S-mephenytoin poor metabolizer phenotype in Caucasians.
Ibeanu GC; Blaisdell J; Ghanayem BI; Beyeler C; Benhamou S; Bouchardy C; Wilkinson GR; Dayer P; Daly AK; Goldstein JA
Pharmacogenetics; 1998 Apr; 8(2):129-35. PubMed ID: 10022751
[TBL] [Abstract][Full Text] [Related]
12. Use of omeprazole as a probe drug for CYP2C19 phenotype in Swedish Caucasians: comparison with S-mephenytoin hydroxylation phenotype and CYP2C19 genotype.
Chang M; Dahl ML; Tybring G; Götharson E; Bertilsson L
Pharmacogenetics; 1995 Dec; 5(6):358-63. PubMed ID: 8747407
[TBL] [Abstract][Full Text] [Related]
13. Bantu Tanzanians have a decreased capacity to metabolize omeprazole and mephenytoin in relation to their CYP2C19 genotype.
Herrlin K; Massele AY; Jande M; Alm C; Tybring G; Abdi YA; Wennerholm A; Johansson I; Dahl ML; Bertilsson L; Gustafsson LL
Clin Pharmacol Ther; 1998 Oct; 64(4):391-401. PubMed ID: 9797796
[TBL] [Abstract][Full Text] [Related]
14. Debrisoquin and S-mephenytoin hydroxylation phenotypes and CYP2D6 genotypes in an Estonian population.
Marandi T; Dahl ML; Kiivet RA; Rägo L; Sjöqvist F
Pharmacol Toxicol; 1996 May; 78(5):303-7. PubMed ID: 8737964
[TBL] [Abstract][Full Text] [Related]
15. Identification of new human CYP2C19 alleles (CYP2C19*6 and CYP2C19*2B) in a Caucasian poor metabolizer of mephenytoin.
Ibeanu GC; Goldstein JA; Meyer U; Benhamou S; Bouchardy C; Dayer P; Ghanayem BI; Blaisdell J
J Pharmacol Exp Ther; 1998 Sep; 286(3):1490-5. PubMed ID: 9732415
[TBL] [Abstract][Full Text] [Related]
16. A multifamily study on the relationship between CYP2C19 genotype and s-mephenytoin oxidation phenotype.
Brøsen K; de Morais SM; Meyer UA; Goldstein JA
Pharmacogenetics; 1995 Oct; 5(5):312-7. PubMed ID: 8563772
[TBL] [Abstract][Full Text] [Related]
17. Frequencies of the defective CYP2C19 alleles responsible for the mephenytoin poor metabolizer phenotype in various Oriental, Caucasian, Saudi Arabian and American black populations.
Goldstein JA; Ishizaki T; Chiba K; de Morais SM; Bell D; Krahn PM; Evans DA
Pharmacogenetics; 1997 Feb; 7(1):59-64. PubMed ID: 9110363
[TBL] [Abstract][Full Text] [Related]
18. Differences in the incidence of the CYP2C19 polymorphism affecting the S-mephenytoin phenotype in Chinese Han and Bai populations and identification of a new rare CYP2C19 mutant allele.
Xiao ZS; Goldstein JA; Xie HG; Blaisdell J; Wang W; Jiang CH; Yan FX; He N; Huang SL; Xu ZH; Zhou HH
J Pharmacol Exp Ther; 1997 Apr; 281(1):604-9. PubMed ID: 9103550
[TBL] [Abstract][Full Text] [Related]
19. Phenotyping of CYP2C19 with enantiospecific HPLC-quantification of R- and S-mephenytoin and comparison with the intron4/exon5 G-->A-splice site mutation.
Brockmöller J; Rost KL; Gross D; Schenkel A; Roots I
Pharmacogenetics; 1995 Apr; 5(2):80-8. PubMed ID: 7663532
[TBL] [Abstract][Full Text] [Related]
20. Debrisoquine and S-mephenytoin hydroxylation polymorphisms in a Russian population living in Estonia.
Marandi T; Dahl ML; Rägo L; Kiivet R; Sjöqvist F
Eur J Clin Pharmacol; 1997; 53(3-4):257-60. PubMed ID: 9476041
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]